Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Hims & Hers Health ($HIMS) stock recently earned a new Buy rating from Barclays at a price target of $48. Barclays sees ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Delving into the details, we found 53% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $373,316, and 7 were calls, valued ...

Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.

Hims and Hers first announced its expansion into Canada in early July, taking the opportunity as Danish pharmaceutical giant ...

Shares of Hims & Hers are trending Thursday morning. The San Francisco-based telehealth company announced an international ...